Shares of Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) rose 5.9% on Thursday . The stock traded as high as $14.99 and last traded at $14.97, with a volume of 53,674 shares changing hands. The stock had previously closed at $14.14.

CRVS has been the subject of several research reports. Credit Suisse Group AG initiated coverage on shares of Corvus Pharmaceuticals in a report on Monday, April 18th. They issued an “outperform” rating and a $25.00 target price for the company. Guggenheim initiated coverage on shares of Corvus Pharmaceuticals in a report on Monday, April 18th. They issued a “buy” rating and a $24.00 target price for the company. Cowen and Company initiated coverage on shares of Corvus Pharmaceuticals in a report on Monday, April 18th. They issued an “outperform” rating for the company. Cantor Fitzgerald started coverage on shares of Corvus Pharmaceuticals in a report on Monday, April 18th. They issued a “buy” rating and a $23.00 target price for the company. Finally, BTIG Research started coverage on shares of Corvus Pharmaceuticals in a research note on Tuesday, April 19th. They issued a “buy” rating and a $22.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average target price of $21.60.

The company has a 50-day moving average of $13.63 and a 200-day moving average of $13.63. The firm’s market capitalization is $305.48 million.

In other news, major shareholder A/S Novo acquired 70,000 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Thursday, May 12th. The shares were acquired at an average price of $10.00 per share, with a total value of $700,000.00. Following the completion of the purchase, the insider now owns 3,224,046 shares of the company’s stock, valued at approximately $32,240,460. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Richard A. Md Miller acquired 30,300 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Friday, May 13th. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $303,000.00. The disclosure for this purchase can be found here.

Corvus Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of agents, which target the immune system to treat patients with cancer. The Company is developing drugs and antibodies that block crucial immune checkpoints, and reprogram immune T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.